| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
34,860,000 |
| Market
Cap: |
1.91(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$34.28 - $67.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Gemeni Therapeutics is a clinical-stage precision medicine company developing therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). Co.'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein and is designed to address complement hyperactivity and overall dysregulation caused by loss of function mutations thus restoring retinal health in patients with AMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
388,891 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,000,076 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
13,773 |
774,655 |
858,272 |
3,480,717 |
| Total Sell Value |
$693,814 |
$42,063,464 |
$47,256,888 |
$198,392,792 |
| Total People Sold |
2 |
8 |
9 |
14 |
| Total Sell Transactions |
4 |
24 |
37 |
84 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Savage William Jacob |
Chief Medical Officer |
• – – |
2025-06-27 |
4 |
OE |
$9.86 |
$316,210 |
D/D |
32,070 |
88,795 |
|
- |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2025-06-16 |
4 |
AS |
$52.26 |
$104,519 |
D/D |
(2,000) |
67,530 |
|
5% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-06-06 |
4 |
AS |
$50.00 |
$149,800 |
D/D |
(2,996) |
56,725 |
|
9% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-05-20 |
4 |
AS |
$50.04 |
$334,128 |
D/D |
(6,677) |
59,721 |
|
9% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-05-02 |
4 |
AS |
$50.17 |
$105,367 |
D/D |
(2,100) |
66,398 |
|
10% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-04-07 |
4 |
OE |
$1.01 |
$7,070 |
D/D |
7,000 |
161,828 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-21 |
4 |
S |
$54.00 |
$540,594 |
I/I |
(10,011) |
187,297 |
|
-2% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-21 |
4 |
S |
$54.00 |
$540,594 |
I/I |
(10,011) |
187,297 |
|
-2% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-20 |
4 |
S |
$54.01 |
$149,176 |
I/I |
(2,762) |
188,617 |
|
0% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-20 |
4 |
S |
$54.01 |
$149,176 |
I/I |
(2,762) |
188,617 |
|
0% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-19 |
4 |
S |
$54.02 |
$2,142,217 |
I/I |
(39,656) |
188,981 |
|
1% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-19 |
4 |
S |
$54.02 |
$2,142,217 |
I/I |
(39,656) |
188,981 |
|
1% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-12 |
4 |
S |
$54.44 |
$4,529,507 |
I/I |
(83,182) |
194,209 |
|
1% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-12 |
4 |
S |
$54.44 |
$4,529,507 |
I/I |
(83,182) |
194,209 |
|
1% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-11 |
4 |
S |
$54.01 |
$1,461,295 |
I/I |
(27,056) |
205,175 |
|
1% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-11 |
4 |
S |
$54.01 |
$1,461,295 |
I/I |
(27,056) |
205,175 |
|
1% |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-03-10 |
4 |
S |
$54.29 |
$10,974,794 |
I/I |
(202,146) |
208,742 |
|
0% |
|
| Ashiya Mona |
Director |
– • – |
2025-03-10 |
4 |
S |
$54.29 |
$10,974,794 |
I/I |
(202,146) |
208,742 |
|
0% |
|
| Stephenson Pamela |
Chief Commercial Officer |
• – – |
2025-02-18 |
4 |
S |
$54.58 |
$171,217 |
D/D |
(3,137) |
69,529 |
|
0% |
|
| Yu Jonathan Yen-Wen |
Chief Operating Officer |
• – – |
2025-02-18 |
4 |
S |
$54.58 |
$87,874 |
D/D |
(1,610) |
40,555 |
|
0% |
|
| Franchi Jean M. |
Chief Financial Officer |
• – – |
2025-02-18 |
4 |
S |
$54.58 |
$171,163 |
D/D |
(3,136) |
69,530 |
|
0% |
|
| Khara Rahul |
Chief Legal Officer |
• – – |
2025-02-18 |
4 |
S |
$54.58 |
$63,367 |
D/D |
(1,161) |
37,583 |
|
0% |
|
| Savage William Jacob |
Chief Medical Officer |
• – – |
2025-02-18 |
4 |
S |
$54.58 |
$89,402 |
D/D |
(1,638) |
68,498 |
|
0% |
|
| Quisel John D |
Chief Executive Officer |
• • – |
2025-02-18 |
4 |
S |
$54.58 |
$304,229 |
D/D |
(5,574) |
154,828 |
|
0% |
|
| Stephenson Pamela |
Chief Commercial Officer |
• – – |
2025-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
36,000 |
72,666 |
|
- |
|
186 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
1.58 (2.97%) 
